Essential role of p21/waf1 in the mediation of the anti-proliferative effects of GHRH antagonist JMR-132

Journal of Molecular Endocrinology

Volumn 41, Issue 5-6, 2008, Pages 389-392

  Volakaki, Aspasia Athina ^a   Lafkas, Daniel ^a   Kassi, Eva ^a   Schally, Andrew V ^b,c   Papavassiliou, Athanasios G ^a   Kiaris, Hippokratis ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; GROWTH HORMONE RELEASING FACTOR ANTAGONIST; HORMONE ANTAGONIST; JMR 132; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; EPITHELIUM CELL; HUMAN; HUMAN CELL; LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GROWTH HORMONE-RELEASING HORMONE; HUMANS; MICE; RNA, SMALL INTERFERING; SERMORELIN;

EID: 57749104694     PISSN: 09525041     EISSN: None     Source Type: Journal    
DOI: 10.1677/JME-08-0106     Document Type: Article

References (14)

1. Barabutis N, Tsellou E, Schally AV, Kouloheri S, Kalofoutis A & Kiaris H 2007 Stimulation of proliferation of MCF-7 breast cancer cells by a transfected splice variant of growth hormone-releasing hormone receptor. PNAS 104 5575-5579.
2. Buchholz S, Schally AV, Engel JB, Hohla F, Heinrich E, Koester F, Varga JL & Halmos G 2007 Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel. PNAS 104 1943-1946.
3. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW & Vogelstein B 1993 WAF1, a potential mediator of p53 tumor suppression. Cell 75 817-825.
4. Kiaris H, Schally AV, Busto R, Halmos G, Artavanis-Tsakonas S & Varga JL 2002 Expression of splice variant for GHRH receptor SV1 mediates mitogenic effects in 3T3 fibroblasts. PNAS 99 196-200.
5. Kiaris H, Chatzistamou I, Schally AV, Halmos G, Varga JL, Koutselini H & Kalofoutis A 2003a Ligand-dependent and -independent effects of GHRH receptor splice variant 1. PNAS 100 9512-9517.
6. Kiaris H, Koutsilieris M, Kalofoutis A & Schally AV 2003b Growth hormone - releasing hormone (GHRH) and extra-pituitary tumorigenesis: therapeutic and diagnostic applications of GHRH antagonists (review). Expert Opinion on Investigational Drugs 12 1385-1394.
7. Kiaris H, Schally AV & Kalofoutis A 2005 Extra-pituitary effects of growth hormone - releasing hormone. Vitamins and Hormones 70 1-24.
8. Pombo CM, Zalvide J, Gaylinn BD & Diéguez C 2000 Growth hormone-releasing hormone stimulates mitogen-activated protein kinase. Endocrinology 141 2113-2119.
9. Rekasi Z, Czompoly T, Schally AV & Halmos G 2000 Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. PNAS 97 10561-10566.
10. Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, Varga JL & Halmos G 2001 Hypothalamic hormones and cancer. Frontiers in Neuroendocrinology 22 248-291.
11. Schally AV, Varga JL & Engel JB 2008 Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nature Clinical Practice. Endocrinology & Metabolism 4 33-43.
12. Siriwardana G, Bradford A, Coy D & Zeitler P 2006 Autocrine/paracrine regulation of breast cancer cell proliferation by growth hormone releasing hormone via Ras, Raf, and mitogen-activated protein kinase. Molecular Endocrinology 20 2010-2019.
13. Solloso A, Barreiro L, Seoane R, Nogueira E, Cañibano C, Alvarez CV, Zalvide J, Diéguez C & Pombo CM 2008 GHRH proliferative action on somatotrophs is cell-type specific and dependent on Pit-1/GHF-1 expression. Journal of Cellular Physiology 215 140-150.
14. Weiss RH 2003 p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 4 425-429.